Corbus Pharmaceuticals Stock Drops After CRB-701 Trial Update
Corbus drug CRB-701 showed early cancer activity, but mixed results and small trials led stock to drop 26%. Larger study ahead.
/ 352 items
#XY Event-Driven Stocks↓
FDA Overturns Rejection: Outlook Therapeutics to Resubmit Lytenava in June
Outlook Therapeutics jumps after FDA appeal win; plans June 2026 resubmission of Lytenava, with possible approval in summer.
Eli Lilly Spends Nearly $4 Billion to Enter the Vaccine Market
Eli Lilly is buying 3 vaccine firms for up to $4B to expand beyond diabetes and obesity into infectious disease vaccines.
Gilead’s Hepcludex Becomes First Approved Treatment for Chronic Hepatitis Delta
FDA approves first HDV drug Hepcludex in US after prior rejection; lowers virus, but needs monitoring for safety risks.
Merck & Kelun’s sac-TMT Combo Cuts Lung Cancer Progression Risk by 65% vs Keytruda
Positive Phase 3 data shows Merck and Kelun’s sac-TMT combined with Keytruda reduced the risk of progression or death by 65% vs Keytruda alone in first-line PD-L1+ NSCLC.
Parkinson’s Drug Targeting LRRK2 Fails Key Phase 2 Trial, Biogen and Denali Halt Development
Experimental Parkinson’s drug BIIB122 failed to slow disease in trials despite strong biological effects; development stopped.